One more bispecific, humanized IgG1 antibody that is definitely under investigation is zenocutuzumab (MCLA-128), which functions by way of two independent mechanisms of motion: inhibition of HER2–HER3 signalling and elimination of tumour cells via ADCC. MCLA-128 functions via a ‘dock and block’ system whereby one particular arm of your antibody https://www.directivepublications.org/journal-of-clinical-breast-cancer/